New Zealand Health Terminology Service (NZHTS) Implementation Guide
0.1.0 - ci-build
New Zealand Health Terminology Service (NZHTS) Implementation Guide
0.1.0 - ci-build
New Zealand Health Terminology Service (NZHTS) Implementation Guide, published by Health New Zealand | Te Whatu Ora. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/daniel-thomson/nzhts/ and changes regularly. See the Directory of published versions
| Active as of 2024-06-05 |
<ValueSet xmlns="http://hl7.org/fhir">
<id value="canshare-sact-regimen-code"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2024-07-25T17:28:39.177+12:00"/>
</meta>
<language value="en-x-sctlang-23162100-0210105"/>
<url
value="https://nzhts.digital.health.nz/fhir/ValueSet/canshare-sact-regimen-code"/>
<identifier>
<system value="http://canshare.co.nz/fhir/NamingSystem/valuesets"/>
<value value="canshare-sact-regimen-code"/>
</identifier>
<version value="0.1.0"/>
<name value="canshare-sact-regimen-code"/>
<title value="NZ SACT regimen code"/>
<status value="active"/>
<experimental value="false"/>
<date value="2024-06-05"/>
<publisher value="Health New Zealand | Te Whatu Ora"/>
<contact>
<name value="Health New Zealand | Te Whatu Ora"/>
<telecom>
<system value="url"/>
<value value="https://www.tewhatuora.govt.nz/"/>
</telecom>
</contact>
<description
value="Systemic anti-cancer therapy (SACT) regimens published by the New Zealand Medicines Formulary in the SACT Regimen Library."/>
<compose>
<include>
<system value="http://snomed.info/sct"/>
<version value="http://snomed.info/sct/21000210109"/>
<filter>
<property value="constraint"/>
<op value="="/>
<value
value="< 61371000210101 |Systemic anti cancer therapy regimen (regime/therapy)|"/>
</filter>
</include>
<include>
<system
value="http://canshare.co.nz/fhir/CodeSystem/snomed-unpublished"/>
<concept>
<code value="392611000210105"/>
<display value="BR Metastatic - cARBOplatin [2 AUC] and gemcitabine"/>
</concept>
<concept>
<code value="392601000210108"/>
<display value="BR Metastatic - ribociclib"/>
</concept>
<concept>
<code value="392591000210103"/>
<display
value="LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under]"/>
</concept>
<concept>
<code value="392581000210100"/>
<display
value="LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under]"/>
</concept>
<concept>
<code value="392571000210102"/>
<display
value="LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under]"/>
</concept>
<concept>
<code value="392561000210108"/>
<display
value="LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]"/>
</concept>
<concept>
<code value="392551000210105"/>
<display value="LEU - GMALL T-LBL 1/2004 triple prophylaxis"/>
</concept>
<concept>
<code value="392541000210107"/>
<display value="LEU - GMALL T-LBL 1/2004 CYCLO/ARAC"/>
</concept>
<concept>
<code value="392531000210104"/>
<display value="LEU - GMALL T-LBL 1/2004 VM26/ARAC"/>
</concept>
<concept>
<code value="392521000210101"/>
<display value="LEU - GMALL T-LBL 1/2004 Reinduction"/>
</concept>
<concept>
<code value="392511000210106"/>
<display value="LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years]"/>
</concept>
<concept>
<code value="392501000210109"/>
<display
value="LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years]"/>
</concept>
<concept>
<code value="392491000210104"/>
<display
value="LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years]"/>
</concept>
<concept>
<code value="392481000210101"/>
<display
value="LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years]"/>
</concept>
<concept>
<code value="392471000210103"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392461000210109"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392451000210106"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392441000210108"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392431000210100"/>
<display
value="LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years]"/>
</concept>
<concept>
<code value="392421000210102"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="392411000210107"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="392401000210105"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant]"/>
</concept>
<concept>
<code value="392391000210107"/>
<display
value="LEU - UKALL14 with RITUximab [not for transplant] Maintenance"/>
</concept>
<concept>
<code value="392381000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="392371000210108"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="392361000210102"/>
<display
value="LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="392351000210100"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant]"/>
</concept>
<concept>
<code value="392341000210103"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392331000210106"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392321000210109"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392311000210104"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392301000210101"/>
<display
value="LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under]"/>
</concept>
<concept>
<code value="392291000210100"/>
<display
value="LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392281000210102"/>
<display
value="LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="391941000210106"/>
<display
value="LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="391931000210103"/>
<display
value="LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="391921000210100"/>
<display
value="LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years]"/>
</concept>
<concept>
<code value="391911000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="391901000210108"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="391891000210107"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="391881000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction"/>
</concept>
<concept>
<code value="391871000210108"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant]"/>
</concept>
<concept>
<code value="391861000210102"/>
<display
value="LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under]"/>
</concept>
<concept>
<code value="391851000210100"/>
<display
value="LEU - UKALL14 Consolidation [Cycle 1] [40 years and under]"/>
</concept>
<concept>
<code value="391841000210103"/>
<display
value="LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under]"/>
</concept>
<concept>
<code value="391831000210106"/>
<display
value="LEU - UKALL14 Phase 1 Induction [40 years and under]"/>
</concept>
<concept>
<code value="391821000210109"/>
<display value="LEU ALL - UKALL14 [40 years and under]"/>
</concept>
<concept>
<code value="391811000210104"/>
<display
value="LEU - UKALL14 with RITUximab Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="391801000210101"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="391791000210100"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="391781000210102"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="391771000210104"/>
<display
value="LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="391761000210105"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction"/>
</concept>
<concept>
<code value="391751000210107"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant]"/>
</concept>
<concept>
<code value="391741000210109"/>
<display value="LEU - AIDA consolidation 3 [over 70 years]"/>
</concept>
<concept>
<code value="391731000210101"/>
<display value="LEU - AIDA consolidation 2 [over 70 years]"/>
</concept>
<concept>
<code value="391721000210103"/>
<display value="LEU - AIDA consolidation 1 [over 70 years]"/>
</concept>
<concept>
<code value="391711000210108"/>
<display value="LEU - AIDA induction [over 70 years]"/>
</concept>
<concept>
<code value="391701000210106"/>
<display
value="LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years]"/>
</concept>
<concept>
<code value="391691000210106"/>
<display
value="LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"/>
</concept>
<concept>
<code value="391681000210109"/>
<display
value="LEU - Pethema LPA2005 maintenance [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391671000210107"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391661000210101"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391621000210108"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391601000210100"/>
<display
value="LEU - Pethema LPA2005 induction [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391591000210105"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391581000210108"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391571000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391561000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391551000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391541000210101"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391531000210109"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391521000210107"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391511000210102"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391501000210104"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391491000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391481000210107"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391471000210105"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391461000210104"/>
<display value="GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC]"/>
</concept>
<concept>
<code value="391451000210102"/>
<display value="GU URO Advanced - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="391441000210100"/>
<display
value="GU URO Advanced - cISplatin [split dose] and gemcitabine"/>
</concept>
<concept>
<code value="391431000210108"/>
<display
value="GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine"/>
</concept>
<concept>
<code value="391421000210106"/>
<display
value="GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin]"/>
</concept>
<concept>
<code value="391411000210101"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312741000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312731000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312721000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312711000210104"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312701000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312691000210101"/>
<display
value="LEU - Pethema LPA2005 maintenance [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312681000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312671000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312661000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312651000210108"/>
<display
value="LEU - Pethema LPA2005 induction [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312631000210102"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312621000210104"/>
<display
value="LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312611000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312601000210107"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312591000210102"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312581000210104"/>
<display
value="LEU - Pethema LPA2005 induction [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312571000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312561000210107"/>
<display value="LEU - UKALL14 Maintenance"/>
</concept>
<concept>
<code value="312551000210109"/>
<display value="LEU - UKALL14 Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="312541000210106"/>
<display
value="LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years]"/>
</concept>
<concept>
<code value="312531000210103"/>
<display value="LEU - UKALL14 Consolidation [Cycle 2]"/>
</concept>
<concept>
<code value="312521000210100"/>
<display
value="LEU - UKALL14 Consolidation [Cycle 1] [over 40 years]"/>
</concept>
<concept>
<code value="312511000210105"/>
<display
value="LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years]"/>
</concept>
<concept>
<code value="312501000210108"/>
<display value="LEU - UKALL14 - Phase 2 Induction"/>
</concept>
<concept>
<code value="312491000210103"/>
<display value="LEU - UKALL14 [over 40 years] - Phase 1 Induction"/>
</concept>
<concept>
<code value="312481000210100"/>
<display value="LEU ALL - UKALL14 [over 40 years]"/>
</concept>
<concept>
<code value="312471000210102"/>
<display
value="LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="312461000210108"/>
<display value="LYM - DA-R-EPOCH LEVEL 6"/>
</concept>
<concept>
<code value="312451000210105"/>
<display value="LYM - DA-R-EPOCH LEVEL 5"/>
</concept>
<concept>
<code value="312441000210107"/>
<display value="LYM - DA-R-EPOCH LEVEL 4"/>
</concept>
<concept>
<code value="312431000210104"/>
<display value="LYM - DA-R-EPOCH LEVEL 3"/>
</concept>
<concept>
<code value="312421000210101"/>
<display value="LYM - DA-R-EPOCH LEVEL 2"/>
</concept>
<concept>
<code value="312411000210106"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 3"/>
</concept>
<concept>
<code value="312401000210109"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 2"/>
</concept>
<concept>
<code value="312391000210106"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 1"/>
</concept>
<concept>
<code value="312381000210109"/>
<display value="LYM - DA-R-EPOCH LEVEL 1"/>
</concept>
<concept>
<code value="312371000210107"/>
<display
value="LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels]"/>
</concept>
<concept>
<code value="312361000210101"/>
<display
value="LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312351000210104"/>
<display
value="LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312341000210102"/>
<display
value="LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312331000210105"/>
<display
value="LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312321000210108"/>
<display
value="LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under]"/>
</concept>
<concept>
<code value="312311000210103"/>
<display value="LEU - HyperCVAD POMP Maintenance"/>
</concept>
<concept>
<code value="312301000210100"/>
<display
value="LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312291000210104"/>
<display
value="LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312281000210101"/>
<display
value="LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312271000210103"/>
<display
value="LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312261000210109"/>
<display
value="LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years]"/>
</concept>
<concept>
<code value="312251000210106"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W]"/>
</concept>
<concept>
<code value="312241000210108"/>
<display value="SAR Ewing sarcoma - VAC, VC and IE [Q2W]"/>
</concept>
<concept>
<code value="312231000210100"/>
<display
value="SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312221000210102"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312211000210107"/>
<display
value="SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312201000210105"/>
<display
value="SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312191000210108"/>
<display
value="SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312181000210106"/>
<display
value="SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312171000210109"/>
<display
value="SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312161000210103"/>
<display
value="SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312151000210101"/>
<display
value="SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]"/>
</concept>
<concept>
<code value="312141000210104"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W]"/>
</concept>
<concept>
<code value="312131000210107"/>
<display value="SAR Ewing sarcoma - VAC, VC and IE [Q3W]"/>
</concept>
<concept>
<code value="312121000210105"/>
<display value="SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W]"/>
</concept>
<concept>
<code value="312111000210100"/>
<display value="SAR - IE [IFOSfamide and etoposide][Q3W]"/>
</concept>
<concept>
<code value="312101000210102"/>
<display
value="SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W]"/>
</concept>
<concept>
<code value="312091000210109"/>
<display value="SAR Ewing sarcoma - VDC, VC and IE [Q3W]"/>
</concept>
<concept>
<code value="312081000210107"/>
<display value="SAR - MA [metHOTREXATe and DOXOrubicin]"/>
</concept>
<concept>
<code value="312071000210105"/>
<display value="SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"/>
</concept>
<concept>
<code value="312061000210104"/>
<display
value="SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"/>
</concept>
<concept>
<code value="312051000210102"/>
<display value="PCN MM - pamidronate 90mg Q4W"/>
</concept>
<concept>
<code value="312041000210100"/>
<display
value="LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2]"/>
</concept>
<concept>
<code value="312031000210108"/>
<display value="LEU ALL precursor B-cell - blinatumomab [CNS3]"/>
</concept>
<concept>
<code value="312021000210106"/>
<display value="CRC REC Locally advanced - dostarlimab"/>
</concept>
<concept>
<code value="312011000210101"/>
<display value="CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles"/>
</concept>
<concept>
<code value="312001000210103"/>
<display value="CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles"/>
</concept>
<concept>
<code value="311991000210101"/>
<display value="CRC - CAPOX 6 cycles"/>
</concept>
<concept>
<code value="311981000210103"/>
<display
value="CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy"/>
</concept>
<concept>
<code value="311971000210100"/>
<display value="CRC Metastatic - irinotecan [Q3W] dose reduced"/>
</concept>
<concept>
<code value="311961000210106"/>
<display value="CRC Metastatic - CETUximab Q2W"/>
</concept>
<concept>
<code value="311951000210108"/>
<display
value="CRC Metastatic - trifluridine/tipiracil and beVACizumab"/>
</concept>
<concept>
<code value="311941000210105"/>
<display value="CRC Metastatic - trifluridine/tipiracil"/>
</concept>
<concept>
<code value="311931000210102"/>
<display value="CRC Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="311921000210104"/>
<display value="CRC Locally advanced - ipilimumab and nivolumab"/>
</concept>
<concept>
<code value="311911000210109"/>
<display value="CRC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="311901000210107"/>
<display value="CRC Metastatic - CETUximab [Q2W] and encorafenib"/>
</concept>
<concept>
<code value="311891000210106"/>
<display value="CRC Metastatic - CETUximab [Q2W] and daBRAFEnib"/>
</concept>
<concept>
<code value="311881000210109"/>
<display value="LEU - AIDA consolidation 3 [70 years and under]"/>
</concept>
<concept>
<code value="311871000210107"/>
<display value="LEU - AIDA consolidation 2 [70 years and under]"/>
</concept>
<concept>
<code value="311861000210101"/>
<display value="LEU - AIDA consolidation 1 [70 years and under]"/>
</concept>
<concept>
<code value="311851000210104"/>
<display value="LEU - AIDA induction [70 years and under]"/>
</concept>
<concept>
<code value="311841000210102"/>
<display
value="LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under]"/>
</concept>
<concept>
<code value="311831000210105"/>
<display
value="LEU - arsenic trioxide and tretinoin consolidation [AML17]"/>
</concept>
<concept>
<code value="311821000210108"/>
<display
value="LEU - arsenic trioxide and tretinoin induction [AML17]"/>
</concept>
<concept>
<code value="311811000210103"/>
<display
value="LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17]"/>
</concept>
<concept>
<code value="311801000210100"/>
<display value="LEU - APML4 maintenance [61 to 70 years]"/>
</concept>
<concept>
<code value="311791000210104"/>
<display value="LEU - APML4 consolidation 2 [61 to 70 years]"/>
</concept>
<concept>
<code value="311781000210101"/>
<display value="LEU - APML4 consolidation 1 [61 to 70 years]"/>
</concept>
<concept>
<code value="311771000210103"/>
<display value="LEU - APML4 induction [61 to 70 years]"/>
</concept>
<concept>
<code value="311761000210109"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years]"/>
</concept>
<concept>
<code value="311751000210106"/>
<display value="LEU - APML4 maintenance [over 70 years]"/>
</concept>
<concept>
<code value="311741000210108"/>
<display value="LEU - APML4 consolidation 2 [over 70 years]"/>
</concept>
<concept>
<code value="311721000210102"/>
<display value="LEU - APML4 consolidation 1 [over 70 years]"/>
</concept>
<concept>
<code value="311711000210107"/>
<display value="LEU - APML4 induction [over 70 years]"/>
</concept>
<concept>
<code value="311701000210105"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years]"/>
</concept>
<concept>
<code value="311691000210105"/>
<display
value="LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311681000210108"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311671000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311661000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311651000210103"/>
<display
value="LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311641000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311631000210109"/>
<display value="LEU HCL - cladribine and RITUximab"/>
</concept>
<concept>
<code value="311621000210107"/>
<display
value="LEU - arsenic trioxide and tretinoin consolidation [standard risk]"/>
</concept>
<concept>
<code value="311611000210102"/>
<display
value="LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk]"/>
</concept>
<concept>
<code value="311601000210104"/>
<display
value="LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk]"/>
</concept>
<concept>
<code value="311591000210109"/>
<display value="LEU - APML4 maintenance [60 years and under]"/>
</concept>
<concept>
<code value="311581000210107"/>
<display value="LEU - APML4 consolidation 2 [60 years and under]"/>
</concept>
<concept>
<code value="311571000210105"/>
<display value="LEU - APML4 consolidation 1 [60 years and under]"/>
</concept>
<concept>
<code value="311561000210104"/>
<display value="LEU - APML4 induction [60 years and under]"/>
</concept>
<concept>
<code value="311551000210102"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under]"/>
</concept>
<concept>
<code value="311541000210100"/>
<display value="LEU - UKALL14 with daSATinib Maintenance"/>
</concept>
<concept>
<code value="311531000210108"/>
<display
value="LEU - UKALL14 with daSATinib Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="311521000210106"/>
<display
value="LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="311511000210101"/>
<display
value="LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="311501000210103"/>
<display
value="LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311491000210108"/>
<display value="LEU - UKALL14 with daSATinib Phase 2 Induction"/>
</concept>
<concept>
<code value="311481000210106"/>
<display value="LEU - UKALL14 with daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311471000210109"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib"/>
</concept>
<concept>
<code value="311461000210103"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance"/>
</concept>
<concept>
<code value="311451000210101"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="311441000210104"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311431000210107"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="311421000210105"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant]"/>
</concept>
<concept>
<code value="311411000210100"/>
<display
value="LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation"/>
</concept>
<concept>
<code value="311401000210102"/>
<display value="LYM - R-MPV alternating with R-MV"/>
</concept>
<concept>
<code value="311391000210100"/>
<display
value="LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine"/>
</concept>
<concept>
<code value="311381000210102"/>
<display value="LYM - EA [etoposide and cytarabine]"/>
</concept>
<concept>
<code value="311371000210104"/>
<display value="LYM - MT-R"/>
</concept>
<concept>
<code value="311361000210105"/>
<display
value="LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine]"/>
</concept>
<concept>
<code value="311351000210107"/>
<display
value="LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis]"/>
</concept>
<concept>
<code value="311341000210109"/>
<display
value="LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction"/>
</concept>
<concept>
<code value="311331000210101"/>
<display value="LEU CLL Relapsed - aLEMTUzumab [subcut]"/>
</concept>
<concept>
<code value="311321000210103"/>
<display value="LEU CLL - venetoclax and oBINUTUZumab"/>
</concept>
<concept>
<code value="311311000210108"/>
<display value="LEU CLL - RITUximab and bendamustine"/>
</concept>
<concept>
<code value="311301000210106"/>
<display value="LEU CLL Relapsed - aLEMTUzumab [IV]"/>
</concept>
<concept>
<code value="311291000210107"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="311281000210105"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant]"/>
</concept>
<concept>
<code value="311271000210108"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="311261000210102"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311251000210100"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant]"/>
</concept>
<concept>
<code value="311241000210103"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311231000210106"/>
<display value="LEU - dexamethasone 6 mg/m2 days 1 to 5"/>
</concept>
<concept>
<code value="311221000210109"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant]"/>
</concept>
<concept>
<code value="311211000210104"/>
<display value="LYM - oBINUTUZumab maintenance"/>
</concept>
<concept>
<code value="311201000210101"/>
<display value="LYM - bendamustine and oBINUTUZumab"/>
</concept>
<concept>
<code value="311191000210103"/>
<display value="LYM NHL B-cell - bendamustine and oBINUTUZumab"/>
</concept>
<concept>
<code value="311181000210100"/>
<display
value="LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase]"/>
</concept>
<concept>
<code value="311171000210102"/>
<display value="LEU CLL - venetoclax and RITUximab"/>
</concept>
<concept>
<code value="311161000210108"/>
<display value="LEU - imatinib 600"/>
</concept>
<concept>
<code value="311151000210105"/>
<display value="LEU - imatinib 400"/>
</concept>
<concept>
<code value="311141000210107"/>
<display value="LEU CML - imatinib"/>
</concept>
<concept>
<code value="311131000210104"/>
<display
value="LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab"/>
</concept>
<concept>
<code value="311121000210101"/>
<display value="LEU - UKALL60+ Maintenance"/>
</concept>
<concept>
<code value="311111000210106"/>
<display value="LEU - UKALL60+ Consolidation"/>
</concept>
<concept>
<code value="311101000210109"/>
<display value="LEU - UKALL60+ Phase 2 Induction"/>
</concept>
<concept>
<code value="311091000210102"/>
<display value="LEU - UKALL60+ Phase 1 Induction"/>
</concept>
<concept>
<code value="311081000210104"/>
<display value="LEU ALL - UKALL60+ [non-intensive]"/>
</concept>
<concept>
<code value="311071000210101"/>
<display value="LEU - UKALL60+ with daSATinib Maintenance"/>
</concept>
<concept>
<code value="311061000210107"/>
<display value="LEU - UKALL60+ with daSATinib Consolidation"/>
</concept>
<concept>
<code value="311051000210109"/>
<display value="LEU - UKALL60+ with daSATinib Phase 2 Induction"/>
</concept>
<concept>
<code value="311041000210106"/>
<display value="LEU - UKALL60+ with daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311031000210103"/>
<display value="LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib"/>
</concept>
<concept>
<code value="311021000210100"/>
<display value="LEU - UKALL60+ with imatinib Maintenance"/>
</concept>
<concept>
<code value="311011000210105"/>
<display value="LEU - UKALL60+ with imatinib Consolidation"/>
</concept>
<concept>
<code value="311001000210108"/>
<display value="LEU - UKALL60+ with imatinib Phase 2 Induction"/>
</concept>
<concept>
<code value="310991000210109"/>
<display value="LEU - UKALL60+ with imatinib Phase 1 Induction"/>
</concept>
<concept>
<code value="310981000210107"/>
<display value="LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5"/>
</concept>
<concept>
<code value="310971000210105"/>
<display value="LEU ALL BCR-ABL1+ - UKALL60+ with imatinib"/>
</concept>
<concept>
<code value="310961000210104"/>
<display
value="LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"/>
</concept>
<concept>
<code value="310951000210102"/>
<display
value="LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction"/>
</concept>
<concept>
<code value="310941000210100"/>
<display
value="LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation"/>
</concept>
<concept>
<code value="310931000210108"/>
<display
value="LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years]"/>
</concept>
<concept>
<code value="303631000210108"/>
<display
value="LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years]"/>
</concept>
<concept>
<code value="303621000210106"/>
<display
value="LEU - High dose cytarabine and midostaurin consolidation [under 60 years]"/>
</concept>
<concept>
<code value="303611000210101"/>
<display
value="LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years]"/>
</concept>
<concept>
<code value="303601000210103"/>
<display
value="LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years]"/>
</concept>
<concept>
<code value="303591000210108"/>
<display value="LEU - Midostaurin maintenance"/>
</concept>
<concept>
<code value="303581000210106"/>
<display
value="LEU - High dose cytarabine and midostaurin consolidation [60 years and over]"/>
</concept>
<concept>
<code value="303571000210109"/>
<display
value="LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over]"/>
</concept>
<concept>
<code value="303561000210103"/>
<display
value="LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over]"/>
</concept>
<concept>
<code value="303551000210101"/>
<display
value="LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation"/>
</concept>
<concept>
<code value="303541000210104"/>
<display
value="LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction"/>
</concept>
<concept>
<code value="303531000210107"/>
<display
value="LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation"/>
</concept>
<concept>
<code value="303521000210105"/>
<display
value="LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide]"/>
</concept>
<concept>
<code value="303511000210100"/>
<display value="LYM - procarbazine [100 mg daily for 5 days]"/>
</concept>
<concept>
<code value="303501000210102"/>
<display
value="LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over]"/>
</concept>
<concept>
<code value="303491000210107"/>
<display
value="LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over]"/>
</concept>
<concept>
<code value="303481000210105"/>
<display value="LYM NHL B-cell - RITUximab and bendamustine"/>
</concept>
<concept>
<code value="303471000210108"/>
<display value="LYM NHL B-cell - RITUximab Maintenance Q8W"/>
</concept>
<concept>
<code value="303461000210102"/>
<display value="LYM NHL B-cell - RITUximab Q1W"/>
</concept>
<concept>
<code value="303451000210100"/>
<display
value="GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab"/>
</concept>
<concept>
<code value="303441000210103"/>
<display
value="GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab"/>
</concept>
<concept>
<code value="274651000210101"/>
<display
value="GYN CX Advanced - cISplatin, PACLItaxel and beVACizumab"/>
</concept>
<concept>
<code value="265811000210107"/>
<display value="LYM NHL - vinCRISTine and prEDNISone [pre-phase]"/>
</concept>
<concept>
<code value="265801000210105"/>
<display
value="LYM NHL B-cell PCNSL - high dose metHOTREXATe 8 g/m2"/>
</concept>
<concept>
<code value="265791000210106"/>
<display
value="LYM NHL B-cell - CYCLOPHOSPHamide and prEDNIsone [pre-phase]"/>
</concept>
<concept>
<code value="265781000210109"/>
<display
value="LYM Relapsed - GIVE [filgrastim, IFOSFamide, etoposide and epirubicin]"/>
</concept>
<concept>
<code value="265771000210107"/>
<display
value="LYM Relapsed - DHAP [dexamethasone, high dose cytarabine and cISplatin]"/>
</concept>
<concept>
<code value="265761000210101"/>
<display
value="LYM NHL NK/T-cell Extra Nodal - Level 2 [100%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]"/>
</concept>
<concept>
<code value="265751000210104"/>
<display
value="LYM NHL NK/T-cell Extra Nodal - Level 1 [67%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]"/>
</concept>
<concept>
<code value="265741000210102"/>
<display
value="LYM NHL B-cell Relapsed - R-DHAP [RITUximab, dexamethasone, high dose cytarabine and cISplatin]"/>
</concept>
<concept>
<code value="265731000210105"/>
<display
value="Neuroendocrine neoplasm Advanced - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="265721000210108"/>
<display
value="Neuroendocrine carcinoma Advanced - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="265711000210103"/>
<display
value="Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation"/>
</concept>
<concept>
<code value="265701000210100"/>
<display
value="Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation"/>
</concept>
<concept>
<code value="265691000210100"/>
<display value="Desmoid fibromatosis - metHOTREXATe and vinBLASTine"/>
</concept>
<concept>
<code value="265681000210102"/>
<display value="SAR STS Metastatic - DOCEtaxel and gemcitabine 900"/>
</concept>
<concept>
<code value="265671000210104"/>
<display
value="SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis]"/>
</concept>
<concept>
<code value="265661000210105"/>
<display value="SAR STS Advanced - trabectedin"/>
</concept>
<concept>
<code value="265651000210107"/>
<display value="SAR STS Advanced - pAZOPanib"/>
</concept>
<concept>
<code value="265641000210109"/>
<display value="SAR STS Advanced - IFOSFamide [3-day]"/>
</concept>
<concept>
<code value="265631000210101"/>
<display value="SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W]"/>
</concept>
<concept>
<code value="265621000210103"/>
<display value="SAR - IE [IFOSfamide and etoposide][Q2W]"/>
</concept>
<concept>
<code value="265611000210108"/>
<display
value="SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W]"/>
</concept>
<concept>
<code value="265601000210106"/>
<display
value="SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W]"/>
</concept>
<concept>
<code value="265591000210101"/>
<display
value="SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000"/>
</concept>
<concept>
<code value="265581000210103"/>
<display
value="SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000"/>
</concept>
<concept>
<code value="265571000210100"/>
<display
value="SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin"/>
</concept>
<concept>
<code value="265561000210106"/>
<display
value="SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan"/>
</concept>
<concept>
<code value="265551000210108"/>
<display
value="SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide]"/>
</concept>
<concept>
<code value="265541000210105"/>
<display
value="SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin"/>
</concept>
<concept>
<code value="265531000210102"/>
<display
value="LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="265521000210104"/>
<display
value="Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide"/>
</concept>
<concept>
<code value="265511000210109"/>
<display value="Neuroendocrine tumour Advanced - everolimus"/>
</concept>
<concept>
<code value="265501000210107"/>
<display value="Neuroendocrine tumour PANC Advanced - sUNITinib"/>
</concept>
<concept>
<code value="265491000210102"/>
<display
value="Neuroendocrine carcinoma Advanced - cARBOplatin and etoposide"/>
</concept>
<concept>
<code value="265481000210104"/>
<display
value="GU Renal cell Metastatic - beVACizumab and erlotinib"/>
</concept>
<concept>
<code value="265471000210101"/>
<display
value="GU GCT Advanced - EP [etoposide and cISplatin] [3-day]"/>
</concept>
<concept>
<code value="265461000210107"/>
<display
value="GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [3-day]"/>
</concept>
<concept>
<code value="265451000210109"/>
<display
value="GU Bladder Urothelial - cISplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="265441000210106"/>
<display value="GU URO Advanced - avelumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265431000210103"/>
<display
value="GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab"/>
</concept>
<concept>
<code value="265421000210100"/>
<display
value="GU Renal cell Metastatic - cABOZANtinib and nivolumab"/>
</concept>
<concept>
<code value="265411000210105"/>
<display
value="GU Renal cell Metastatic - aXITinib and avelumab [flat dose]"/>
</concept>
<concept>
<code value="265401000210108"/>
<display value="GU - nivolumab maintenance Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265391000210105"/>
<display
value="GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265381000210108"/>
<display value="GU - nivolumab maintenance Q4W [flat dosing]"/>
</concept>
<concept>
<code value="265371000210106"/>
<display value="GU - nivolumab and ipilimumab induction"/>
</concept>
<concept>
<code value="265361000210100"/>
<display
value="GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing]"/>
</concept>
<concept>
<code value="265351000210103"/>
<display
value="GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265341000210101"/>
<display
value="GU Renal cell Metastatic - leNVAtinib and everolimus"/>
</concept>
<concept>
<code value="265331000210109"/>
<display
value="GU Bladder Urothelial - gemcitabine [low dose] chemoradiation"/>
</concept>
<concept>
<code value="265321000210107"/>
<display
value="GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense"/>
</concept>
<concept>
<code value="265311000210102"/>
<display
value="GU Bladder Urothelial Adjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense"/>
</concept>
<concept>
<code value="265301000210104"/>
<display
value="GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [3-day]"/>
</concept>
<concept>
<code value="265291000210103"/>
<display
value="GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [5-day]"/>
</concept>
<concept>
<code value="265281000210100"/>
<display
value="GU Penile Advanced - TPF [DOCEtaxel, cISplatin, fluorouracil]"/>
</concept>
<concept>
<code value="265271000210102"/>
<display value="CRC ACA - cISplatin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="265261000210108"/>
<display value="CRC ACA - mitomycin and capecitabine chemoradiation"/>
</concept>
<concept>
<code value="265251000210105"/>
<display value="CRC ACA - mitomycin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="265241000210107"/>
<display
value="UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and nivolumab"/>
</concept>
<concept>
<code value="265231000210104"/>
<display
value="UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin], pembrolizumab and trastuzumab"/>
</concept>
<concept>
<code value="265221000210101"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and nivolumab"/>
</concept>
<concept>
<code value="265211000210106"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and nivolumab"/>
</concept>
<concept>
<code value="265201000210109"/>
<display
value="CRC Metastatic - CETUximab [Q1W], daBRAFEnib and tRAMEtinib"/>
</concept>
<concept>
<code value="265191000210107"/>
<display value="GU URO Metastatic - PACLItaxel [Q1W]"/>
</concept>
<concept>
<code value="265181000210105"/>
<display
value="GU Renal cell Metastatic - leNVAtinib and pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265171000210108"/>
<display
value="GU Renal cell Advanced - nivolumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265161000210102"/>
<display
value="GU Renal cell Advanced - nivolumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="265151000210100"/>
<display value="GU Renal cell Metastatic - pAZOPanib"/>
</concept>
<concept>
<code value="265141000210103"/>
<display value="GU Renal cell Metastatic - sUNITinib"/>
</concept>
<concept>
<code value="265131000210106"/>
<display value="GU URO Advanced - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265121000210109"/>
<display value="GU URO Advanced - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="265111000210104"/>
<display
value="GU Renal cell Metastatic - aXITinib and pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265101000210101"/>
<display
value="GU Renal cell Metastatic - aXITinib and pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="265091000210108"/>
<display value="GU Renal cell Metastatic - everolimus"/>
</concept>
<concept>
<code value="265081000210106"/>
<display
value="GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265071000210109"/>
<display
value="GU Renal cell Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="265061000210103"/>
<display
value="GU Bladder Urothelial Neoadjuvant - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="265051000210101"/>
<display value="GU BLA - mitomycin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="265041000210104"/>
<display
value="GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [5-day]"/>
</concept>
<concept>
<code value="265031000210107"/>
<display
value="GU GCT Non-seminoma Adjuvant - BEP [bleomycin, etoposide and cISplatin]"/>
</concept>
<concept>
<code value="265021000210105"/>
<display
value="GU GCT Advanced - EP [etoposide and cISplatin] [5-day]"/>
</concept>
<concept>
<code value="265011000210100"/>
<display
value="GU GCT Metastatic - VIP [etoposide, IFOSFamide and cISplatin]"/>
</concept>
<concept>
<code value="265001000210102"/>
<display value="GU URO Advanced - cARBOplatin and gemcitabine"/>
</concept>
<concept>
<code value="264991000210108"/>
<display
value="GU Upper Tract Urothelial Adjuvant - cARBOplatin and gemcitabine"/>
</concept>
<concept>
<code value="264981000210106"/>
<display
value="GU Upper Tract Urothelial Adjuvant - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="264971000210109"/>
<display value="GU Renal cell Metastatic - cABOZANtinib"/>
</concept>
<concept>
<code value="264961000210103"/>
<display value="GU Renal cell Metastatic - aXITinib"/>
</concept>
<concept>
<code value="264951000210101"/>
<display
value="LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="264941000210104"/>
<display value="LEU CML - pONATinib"/>
</concept>
<concept>
<code value="264931000210107"/>
<display value="LYM - GemOx [gemcitabine and oxaliplatin]"/>
</concept>
<concept>
<code value="264921000210105"/>
<display
value="LYM Relapsed - DHAC [dexamethasone, high dose cytarabine and cARBOplatin]"/>
</concept>
<concept>
<code value="264911000210100"/>
<display
value="LYM NHL B-cell Relapsed - R-DHAC [RITUximab, dexamethasone, high dose cytarabine and cARBOplatin]"/>
</concept>
<concept>
<code value="264901000210102"/>
<display
value="LYM NHL B-cell PCNSL Relapsed - modified CYVE [cytarabine and etoposide]"/>
</concept>
<concept>
<code value="264891000210103"/>
<display value="MPN Myelofibrosis - ruxolitinib"/>
</concept>
<concept>
<code value="264881000210100"/>
<display value="LEU HCL - RITUximab"/>
</concept>
<concept>
<code value="264871000210102"/>
<display value="LEU T-PLL Relapsed - pentostatin"/>
</concept>
<concept>
<code value="264861000210108"/>
<display value="LEU T-PLL - aLEMTUzumab [IV]"/>
</concept>
<concept>
<code value="264851000210105"/>
<display
value="LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day]"/>
</concept>
<concept>
<code value="264841000210107"/>
<display
value="LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day]"/>
</concept>
<concept>
<code value="264831000210104"/>
<display
value="LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab"/>
</concept>
<concept>
<code value="264821000210101"/>
<display value="LEU CLL - venetoclax"/>
</concept>
<concept>
<code value="264811000210106"/>
<display value="LEU - daSATinib 140"/>
</concept>
<concept>
<code value="264801000210109"/>
<display value="LEU - daSATinib 100"/>
</concept>
<concept>
<code value="264791000210105"/>
<display value="LEU CML - daSATinib"/>
</concept>
<concept>
<code value="264781000210108"/>
<display value="LEU HCL - cladribine"/>
</concept>
<concept>
<code value="264771000210106"/>
<display value="PCN MM - lenalidomide and dexamethasone"/>
</concept>
<concept>
<code value="264761000210100"/>
<display value="GYN VUL Advanced - ciSplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="264751000210103"/>
<display
value="LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine"/>
</concept>
<concept>
<code value="264741000210101"/>
<display
value="LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine"/>
</concept>
<concept>
<code value="264731000210109"/>
<display
value="SAR Ewing sarcoma Relapsed - irinotecan and temozolomide"/>
</concept>
<concept>
<code value="264721000210107"/>
<display value="Desmoid fibromatosis - metHOTREXATe and vinORELBine"/>
</concept>
<concept>
<code value="264711000210102"/>
<display value="SAR Advanced - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="264701000210104"/>
<display
value="SAR Advanced/Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="264691000210104"/>
<display value="SAR Angiosarcoma Advanced - PACLItaxel"/>
</concept>
<concept>
<code value="264681000210101"/>
<display
value="SAR Advanced - pembrolizumab Q3W [weight-based dosing]"/>
</concept>
<concept>
<code value="264671000210103"/>
<display value="Giant Cell tumour of bone - denosumab"/>
</concept>
<concept>
<code value="264661000210109"/>
<display value="SAR STS Advanced - DOXOrubicin"/>
</concept>
<concept>
<code value="264651000210106"/>
<display
value="SAR Kaposi Sarcoma - pegylated liposomal DOXOrubicin hydrochloride"/>
</concept>
<concept>
<code value="264641000210108"/>
<display
value="LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]"/>
</concept>
<concept>
<code value="264631000210100"/>
<display
value="LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]"/>
</concept>
<concept>
<code value="264621000210102"/>
<display
value="LYM NHL B-cell - R-CVP [RITUximab, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="264611000210107"/>
<display
value="LYM NHL B-cell - R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="264601000210105"/>
<display
value="LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNISone] [IV etoposide]"/>
</concept>
<concept>
<code value="264591000210100"/>
<display
value="LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNIsone] [IV/oral etoposide]"/>
</concept>
<concept>
<code value="264581000210102"/>
<display value="LYM - vinORELBine and gemcitabine"/>
</concept>
<concept>
<code value="264571000210104"/>
<display
value="LYM NHL - CHOP21 [CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="264561000210105"/>
<display
value="LYM NHL B-cell - R-CHOP14 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="264551000210107"/>
<display
value="LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV/oral etoposide]"/>
</concept>
<concept>
<code value="264541000210109"/>
<display
value="LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV etoposide]"/>
</concept>
<concept>
<code value="264531000210101"/>
<display
value="LYM NHL B-cell - R-GDP [RITUximab, gemcitabine, dexamethasone and cISplatin]"/>
</concept>
<concept>
<code value="264521000210103"/>
<display
value="LYM NHL B-cell - R-GCVP [RITUximab, gemcitabine, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="264511000210108"/>
<display
value="LYM - GDP [gemcitabine, dexamethasone and cISplatin]"/>
</concept>
<concept>
<code value="264501000210106"/>
<display
value="LYM - GCD [gemcitabine, cARBOplatin and dexamethasone]"/>
</concept>
<concept>
<code value="264491000210101"/>
<display
value="LYM NHL B-cell - R-GemOX [RITUximab, gemcitabine and oxaliplatin]"/>
</concept>
<concept>
<code value="264481000210103"/>
<display
value="LYM - PEP-C [prEDNISone, CYCLOPHOSPHamide, etoposide and procarbazine]"/>
</concept>
<concept>
<code value="264471000210100"/>
<display value="CRC ACA Advanced - cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="264461000210106"/>
<display
value="CRC Metastatic - CETUximab [Q1W], biNIMEtinib and encorafenib"/>
</concept>
<concept>
<code value="264451000210108"/>
<display value="CRC Metastatic - CETUximab [Q1W] and encorafenib"/>
</concept>
<concept>
<code value="264441000210105"/>
<display value="LEU AML - MidAC [mitoxantrone and cytarabine]"/>
</concept>
<concept>
<code value="264431000210102"/>
<display value="LEU CLL - acalabrutinib"/>
</concept>
<concept>
<code value="264411000210109"/>
<display value="LEU CLL - chlorambucil and oBINUTUZumab"/>
</concept>
<concept>
<code value="264401000210107"/>
<display value="LEU - nilotinib 300"/>
</concept>
<concept>
<code value="264391000210109"/>
<display value="LEU - nilotinib 400"/>
</concept>
<concept>
<code value="264381000210107"/>
<display value="LEU CML - nilotinib"/>
</concept>
<concept>
<code value="264371000210105"/>
<display
value="CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2"/>
</concept>
<concept>
<code value="264361000210104"/>
<display
value="LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide]"/>
</concept>
<concept>
<code value="264351000210102"/>
<display
value="LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide]"/>
</concept>
<concept>
<code value="264341000210100"/>
<display
value="LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine]"/>
</concept>
<concept>
<code value="264331000210108"/>
<display
value="LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema]"/>
</concept>
<concept>
<code value="264321000210106"/>
<display
value="LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone]"/>
</concept>
<concept>
<code value="264311000210101"/>
<display value="LYM NHL B-cell MCL - ibrutinib"/>
</concept>
<concept>
<code value="264301000210103"/>
<display
value="LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]"/>
</concept>
<concept>
<code value="264291000210102"/>
<display
value="LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]"/>
</concept>
<concept>
<code value="264281000210104"/>
<display value="CNS GBM Recurrent - lomustine"/>
</concept>
<concept>
<code value="264271000210101"/>
<display
value="CNS GLI Recurrent - temozolomide [continuous dose-intense] [high grade]"/>
</concept>
<concept>
<code value="264261000210107"/>
<display
value="CNS GBM Recurrent - beVACizumab and irinotecan 125 mg/m2"/>
</concept>
<concept>
<code value="264251000210109"/>
<display
value="CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [high grade]"/>
</concept>
<concept>
<code value="264241000210106"/>
<display
value="CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [low grade]"/>
</concept>
<concept>
<code value="264231000210103"/>
<display
value="LUNG NSCLC Metastatic - vinORELBine 30 [day 1 and 8] Q3W"/>
</concept>
<concept>
<code value="264221000210100"/>
<display value="LUNG NSCLC Metastatic - vinORELBine 25 Q1W"/>
</concept>
<concept>
<code value="264211000210105"/>
<display
value="BR Adjuvant - EC-D [epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]"/>
</concept>
<concept>
<code value="264201000210108"/>
<display value="BR Metastatic - olaparib"/>
</concept>
<concept>
<code value="264191000210106"/>
<display
value="BR NON-Metastatic - D100-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="264181000210109"/>
<display
value="BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W"/>
</concept>
<concept>
<code value="264171000210107"/>
<display
value="BR NON-Metastatic - D75-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="264161000210101"/>
<display
value="BR NON-Metastatic - EC [epirubicin and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="264151000210104"/>
<display value="LEU AML Relapsed - gilteritinib [FLT3 mutated]"/>
</concept>
<concept>
<code value="264141000210102"/>
<display
value="LEU AML Refractory - FLAG-Ida10 [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]"/>
</concept>
<concept>
<code value="264131000210105"/>
<display
value="LEU AML FLT3-ITD mutated Relapsed - azacitidine and soRAFENib"/>
</concept>
<concept>
<code value="264121000210108"/>
<display
value="LEU AML FLT3-ITD mutated - soRAFENib maintenance after allogeneic stem cell transplant"/>
</concept>
<concept>
<code value="264111000210103"/>
<display value="LEU AML - azacitidine [7 day]"/>
</concept>
<concept>
<code value="264101000210100"/>
<display value="LEU AML - azacitidine and venetoclax"/>
</concept>
<concept>
<code value="264091000210107"/>
<display
value="LEU AML - ALFA 9801 [IDArubicin and cytarabine] induction"/>
</concept>
<concept>
<code value="264081000210105"/>
<display
value="LEU AML - MACE [amsacrine, cytarabine and etoposide]"/>
</concept>
<concept>
<code value="264071000210108"/>
<display
value="LUNG NSCLC Locally advanced - durvalumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="264061000210102"/>
<display
value="PCN MM Relapsed - carfilzomib and dexamethasone [Q1W]"/>
</concept>
<concept>
<code value="264051000210100"/>
<display value="PCN MM Relapsed - pomalidomide and dexamethasone"/>
</concept>
<concept>
<code value="264041000210103"/>
<display value="PCN MM Relapsed - daratumumab [subcut]"/>
</concept>
<concept>
<code value="264031000210106"/>
<display
value="PCN MM Relapsed - daratumumab [subcut], bortezomib and dexamethasone [Q3W] followed by daratumumab [subcut] [Q4W]"/>
</concept>
<concept>
<code value="264021000210109"/>
<display
value="PCN MM Relapsed - LenBorDex [lenalidomide, bortezomib, and dexamethasone] Q4W"/>
</concept>
<concept>
<code value="264011000210104"/>
<display
value="PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone"/>
</concept>
<concept>
<code value="264001000210101"/>
<display value="Myelodysplastic syndrome - azacitidine [7 day]"/>
</concept>
<concept>
<code value="263991000210105"/>
<display value="Myelodysplastic syndrome - azacitidine [5 day]"/>
</concept>
<concept>
<code value="263981000210108"/>
<display
value="LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over]"/>
</concept>
<concept>
<code value="263971000210106"/>
<display value="CNS GBM Recurrent - beVACizumab and lomustine"/>
</concept>
<concept>
<code value="263961000210100"/>
<display value="CNS GBM Recurrent - beVACizumab Q2W"/>
</concept>
<concept>
<code value="263951000210103"/>
<display value="CNS GBM Recurrent - beVACizumab Q3W"/>
</concept>
<concept>
<code value="263941000210101"/>
<display value="CNS GLI Recurrent - temozolomide [high grade]"/>
</concept>
<concept>
<code value="263931000210109"/>
<display value="CNS - temozolomide following chemoradiation"/>
</concept>
<concept>
<code value="263921000210107"/>
<display value="CNS - temozolomide chemoradiation"/>
</concept>
<concept>
<code value="263911000210102"/>
<display
value="CNS GBM - temozolomide chemoradiation followed by temozolomide"/>
</concept>
<concept>
<code value="263901000210104"/>
<display
value="LUNG NSCLC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="263891000210100"/>
<display value="LUNG SCLC Extensive - PACLItaxel Q1W"/>
</concept>
<concept>
<code value="263881000210102"/>
<display
value="LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [under 60 years]"/>
</concept>
<concept>
<code value="263871000210104"/>
<display
value="LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [60 years and over]"/>
</concept>
<concept>
<code value="263861000210105"/>
<display
value="LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [under 60 years]"/>
</concept>
<concept>
<code value="263851000210107"/>
<display value="LEU CMML - azacitidine [7 day]"/>
</concept>
<concept>
<code value="263841000210109"/>
<display
value="LEU AML - cytarabine 3 g/m2 [ONCE daily days 1 to 6] consolidation [courses 3 and 4]"/>
</concept>
<concept>
<code value="263831000210101"/>
<display value="LUNG NSCLC Metastatic - gemcitabine"/>
</concept>
<concept>
<code value="263821000210103"/>
<display value="LUNG NSCLC Adjuvant - osimertinib"/>
</concept>
<concept>
<code value="60491000210104"/>
<display value="LEU AML - low dose cytarabine"/>
</concept>
<concept>
<code value="60481000210101"/>
<display value="LEU AML - low dose cytarabine and venetoclax"/>
</concept>
<concept>
<code value="60471000210103"/>
<display
value="LEU AML - DA 3+8 [DAUNOrubicin and cytarabine] induction [course 2]"/>
</concept>
<concept>
<code value="60461000210109"/>
<display
value="LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1]"/>
</concept>
<concept>
<code value="60451000210106"/>
<display
value="LEU AML - cytarabine 3 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [under 60 years]"/>
</concept>
<concept>
<code value="60441000210108"/>
<display
value="LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over]"/>
</concept>
<concept>
<code value="60431000210100"/>
<display
value="LEU AML - cytarabine 3 g/m2 [days 1,2,3] consolidation [courses 3 and 4] [under 60 years]"/>
</concept>
<concept>
<code value="60421000210102"/>
<display
value="LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]"/>
</concept>
<concept>
<code value="60411000210107"/>
<display
value="LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [60 years and over]"/>
</concept>
<concept>
<code value="60401000210105"/>
<display
value="PCN MM - daratumumab [subcut], lenalidomide and dexamethasone"/>
</concept>
<concept>
<code value="60391000210107"/>
<display
value="PCN MM - lenalidomide [continuous dosing] post autologous stem cell transplant"/>
</concept>
<concept>
<code value="60381000210105"/>
<display value="PCN MM - pamidronate 30mg Q4W"/>
</concept>
<concept>
<code value="60371000210108"/>
<display value="PCN MM - zoledronic acid [Q12W]"/>
</concept>
<concept>
<code value="60361000210102"/>
<display value="PCN MM - MP [melphalan and preDNISone]"/>
</concept>
<concept>
<code value="60351000210100"/>
<display
value="PCN MM - MPT [melphalan, prEDNISone and thalidomide]"/>
</concept>
<concept>
<code value="60341000210103"/>
<display
value="PCN MM - lenalidomide [3/1 dosing] post autologous stem cell transplant"/>
</concept>
<concept>
<code value="60331000210106"/>
<display
value="PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] consolidation"/>
</concept>
<concept>
<code value="60321000210109"/>
<display
value="PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction followed by autologous stem cell transplant"/>
</concept>
<concept>
<code value="60311000210104"/>
<display value="PCN MM - ixazomib, lenalidomide and dexamethasone"/>
</concept>
<concept>
<code value="60301000210101"/>
<display
value="PCN MM - CyBorDex Low [CYCLOPHOSPHamide, bortezomib and dexamethasone]"/>
</concept>
<concept>
<code value="60291000210100"/>
<display
value="PCN - CTDa [CYCLOPHOSPHamide, thalidomide and dexamethasone] [attenuated dose]"/>
</concept>
<concept>
<code value="60281000210102"/>
<display
value="PCN MM - CyBorDex High [CYCLOPHOSPHamide, bortezomib and dexamethasone]"/>
</concept>
<concept>
<code value="60271000210104"/>
<display
value="PCN - CTD [CYCLOPHOSPHamide, thalidomide and dexamethasone]"/>
</concept>
<concept>
<code value="60261000210105"/>
<display
value="PCN MM - BTD [bortezomib, thalidomide and dexamethasone] induction"/>
</concept>
<concept>
<code value="60251000210107"/>
<display value="PCN MM - BMP [bortezomib, melphalan and prEDNISone]"/>
</concept>
<concept>
<code value="60241000210109"/>
<display value="MPN - busulfan"/>
</concept>
<concept>
<code value="60231000210101"/>
<display value="HN NPC Metastatic - gemcitabine [Q4W]"/>
</concept>
<concept>
<code value="60221000210103"/>
<display
value="GYN Ovarian germ cell tumour - BEP [bleomycin, etoposide and cISplatin]"/>
</concept>
<concept>
<code value="60211000210108"/>
<display value="GYN OV Recurrent - PACLitaxel [Q1W] and beVACizumab"/>
</concept>
<concept>
<code value="60201000210106"/>
<display value="GYN OV Recurrent - PACLitaxel [Q1W]"/>
</concept>
<concept>
<code value="60191000210109"/>
<display value="CRC Adjuvant - mDe Gramont [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="60181000210107"/>
<display value="CRC Adjuvant - mDe Gramont [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="60171000210105"/>
<display
value="UGI BIL AND GBC Metastatic - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="60161000210104"/>
<display
value="UGI PANC Metastatic - gemcitabine and Abraxane [PACLItaxel nanoparticle albumin bound]"/>
</concept>
<concept>
<code value="60151000210102"/>
<display value="LEU CLL - ibrutinib"/>
</concept>
<concept>
<code value="60141000210100"/>
<display value="LEU CLL - chlorambucil"/>
</concept>
<concept>
<code value="60131000210108"/>
<display value="LEU CLL - chlorambucil [flat dosing]"/>
</concept>
<concept>
<code value="60121000210106"/>
<display value="HN SQCC Metastatic - metHOTREXATe"/>
</concept>
<concept>
<code value="60111000210101"/>
<display
value="HN SQCC NON-Metastatic - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation"/>
</concept>
<concept>
<code value="60101000210103"/>
<display value="HN SQCC NON-Metastatic - CETUximab chemoradiation"/>
</concept>
<concept>
<code value="60091000210105"/>
<display
value="GYN - cARBOplatin and PACLItaxel [following chemoradiation]"/>
</concept>
<concept>
<code value="60081000210108"/>
<display value="GYN - cISplatin chemoradiation"/>
</concept>
<concept>
<code value="60071000210106"/>
<display
value="GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="60061000210100"/>
<display value="GYN OV Recurrent - topotecan"/>
</concept>
<concept>
<code value="60051000210103"/>
<display
value="GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]"/>
</concept>
<concept>
<code value="60041000210101"/>
<display value="GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="60031000210109"/>
<display value="GYN OV Recurrent - topotecan and beVACizumab Q4W"/>
</concept>
<concept>
<code value="60021000210107"/>
<display
value="GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk]"/>
</concept>
<concept>
<code value="60011000210102"/>
<display
value="GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk]"/>
</concept>
<concept>
<code value="60001000210104"/>
<display
value="GYN OV Low grade serous carcinoma - letrozole maintenance"/>
</concept>
<concept>
<code value="59991000210107"/>
<display
value="GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing]"/>
</concept>
<concept>
<code value="59981000210105"/>
<display
value="GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous]"/>
</concept>
<concept>
<code value="59971000210108"/>
<display value="GYN OV Recurrent - etoposide oral"/>
</concept>
<concept>
<code value="59961000210102"/>
<display value="GYN OV Recurrent - gemcitabine"/>
</concept>
<concept>
<code value="59951000210100"/>
<display
value="GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride"/>
</concept>
<concept>
<code value="59941000210103"/>
<display
value="GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab"/>
</concept>
<concept>
<code value="59931000210106"/>
<display
value="GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59921000210109"/>
<display
value="GYN CX Locally advanced - cISplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59911000210104"/>
<display
value="GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk]"/>
</concept>
<concept>
<code value="59901000210101"/>
<display
value="LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing]"/>
</concept>
<concept>
<code value="59891000210102"/>
<display
value="GYN OV Recurrent - cARBOplatin and gemcitabine [day 1 cARBOplatin]"/>
</concept>
<concept>
<code value="59881000210104"/>
<display
value="GYN OV Recurrent - cARBOplatin and pegylated liposomal DOXOrubicin hydrochloride"/>
</concept>
<concept>
<code value="59871000210101"/>
<display
value="GYN OV Recurrent - cARBOplatin, gemcitabine and beVACizumab"/>
</concept>
<concept>
<code value="59861000210107"/>
<display
value="GYN OV Recurrent - cARBOplatin, pegylated liposomal DOXOrubicin hydrochloride and beVACizumab"/>
</concept>
<concept>
<code value="59851000210109"/>
<display
value="GYN GTD - EP [etoposide and cISplatin] [very high risk]"/>
</concept>
<concept>
<code value="59841000210106"/>
<display
value="BR NON-Metastatic - DOCEtaxel, pERTUZumab and trastuzumab"/>
</concept>
<concept>
<code value="59831000210103"/>
<display
value="BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 3/4]"/>
</concept>
<concept>
<code value="59821000210100"/>
<display
value="BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense"/>
</concept>
<concept>
<code value="59811000210105"/>
<display
value="BR Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]"/>
</concept>
<concept>
<code value="59801000210108"/>
<display
value="BR Metastatic - vinORELBine [IV], pERTUZumab and trastuzumab Q3W"/>
</concept>
<concept>
<code value="59791000210109"/>
<display
value="BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3]"/>
</concept>
<concept>
<code value="59781000210107"/>
<display value="BR Metastatic - vinORELBine [oral]"/>
</concept>
<concept>
<code value="59771000210105"/>
<display value="GYN END Advanced - meDROXYPROGESTERone acetate"/>
</concept>
<concept>
<code value="59761000210104"/>
<display
value="GYN OV Advanced - beVACizumab 7.5 mg/kg Q3W [shared care]"/>
</concept>
<concept>
<code value="59751000210102"/>
<display value="GYN OV Advanced - cARBOplatin [primary treatment]"/>
</concept>
<concept>
<code value="59731000210108"/>
<display value="GYN CX Advanced - cISplatin and PACLItaxel"/>
</concept>
<concept>
<code value="59721000210106"/>
<display value="GYN OV Advanced - cARBOplatin and DOCEtaxel"/>
</concept>
<concept>
<code value="59711000210101"/>
<display value="GYN OV Advanced - cARBOplatin and PACLItaxel [Q1W]"/>
</concept>
<concept>
<code value="59701000210103"/>
<display value="GYN OV Advanced - cARBOplatin and PACLitaxel [Q3W]"/>
</concept>
<concept>
<code value="59691000210103"/>
<display
value="GYN OV Advanced - cARBOplatin, PACLItaxel and beVACizumab"/>
</concept>
<concept>
<code value="59681000210100"/>
<display value="GYN OV Recurrent - cARBOplatin"/>
</concept>
<concept>
<code value="59671000210102"/>
<display value="GYN OV Advanced - olaparib"/>
</concept>
<concept>
<code value="59661000210108"/>
<display
value="GYN END Advanced - leNVAtinib and pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="59651000210105"/>
<display
value="GYN OV Advanced - beVACizumab 15 mg/kg Q3W [shared care]"/>
</concept>
<concept>
<code value="59641000210107"/>
<display
value="GYN OV Adjuvant - cARBOplatin and PACLitaxel [early stage]"/>
</concept>
<concept>
<code value="59631000210104"/>
<display value="GYN OV Adjuvant - cARBOplatin [early stage]"/>
</concept>
<concept>
<code value="59621000210101"/>
<display value="GYN GTD - metHOTREXATe [low risk]"/>
</concept>
<concept>
<code value="59591000210104"/>
<display value="GYN GTD - daCTINomycin [low risk]"/>
</concept>
<concept>
<code value="59581000210101"/>
<display value="GYN - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="59571000210103"/>
<display value="GYN - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="59561000210109"/>
<display value="GYN - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="59551000210106"/>
<display value="GYN END Advanced - cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="59541000210108"/>
<display
value="GYN CX Advanced - cARBOplatin, PACLItaxel and beVACizumab"/>
</concept>
<concept>
<code value="59531000210100"/>
<display value="GYN CX Advanced - cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="59521000210102"/>
<display
value="LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 80/100 chemoradiation"/>
</concept>
<concept>
<code value="59511000210107"/>
<display value="HN THY Metastatic - leNVAtinib"/>
</concept>
<concept>
<code value="59501000210105"/>
<display
value="HN SQCC NON-Metastatic - cISplatin [Q3W] post-operative chemoradiation"/>
</concept>
<concept>
<code value="59491000210100"/>
<display
value="HN SQCC Metastatic - cARBOplatin and fluorouracil [Q3W]"/>
</concept>
<concept>
<code value="59481000210102"/>
<display
value="HN NPC NON-Metastatic - cARBOplatin chemoradiation followed by cARBOplatin and fluorouracil"/>
</concept>
<concept>
<code value="59471000210104"/>
<display
value="HN NPC NON-Metastatic - gemcitabine and cISplatin followed by cISplatin chemoradiation"/>
</concept>
<concept>
<code value="59461000210105"/>
<display value="HN SAL Metastatic - cISplatin and vinORELBine [IV]"/>
</concept>
<concept>
<code value="59451000210107"/>
<display
value="HN SQCC NON-Metastatic - cISplatin [Q3W] chemoradiation"/>
</concept>
<concept>
<code value="59441000210109"/>
<display
value="HN NPC NON-Metastatic - cISplatin [Q3W] chemoradiation followed by cISplatin and fluorouracil"/>
</concept>
<concept>
<code value="59431000210101"/>
<display
value="HN SAL Metastatic - CAP [CYCLOPHOSPHamide, DOXOrubicin and cISplatin]"/>
</concept>
<concept>
<code value="59421000210103"/>
<display
value="HN SQCC Metastatic - cISplatin, fluorouracil and pembrolizumab"/>
</concept>
<concept>
<code value="59411000210108"/>
<display value="HN SQCC Metastatic - nivolumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="59401000210106"/>
<display value="HN SQCC Metastatic - PACLItaxel Q1W"/>
</concept>
<concept>
<code value="59391000210108"/>
<display
value="HN SQCC Metastatic - pembrolizumab Q3W [weight-based dosing]"/>
</concept>
<concept>
<code value="59381000210106"/>
<display value="HN NPC Metastatic - gemcitabine and cARBOplatin"/>
</concept>
<concept>
<code value="59371000210109"/>
<display
value="HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab"/>
</concept>
<concept>
<code value="59361000210103"/>
<display value="HN NPC Metastatic - gemcitabine and cISplatin"/>
</concept>
<concept>
<code value="59351000210101"/>
<display value="HN SQCC Metastatic - cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="59341000210104"/>
<display value="HN SQCC Metastatic - cISplatin and fluorouracil"/>
</concept>
<concept>
<code value="59331000210107"/>
<display
value="HN NPC NON-Metastatic - cISplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59321000210105"/>
<display
value="HN SQCC NON-Metastatic - cISplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59311000210100"/>
<display
value="BR NON-Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]"/>
</concept>
<concept>
<code value="59301000210102"/>
<display
value="BR Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]"/>
</concept>
<concept>
<code value="59291000210101"/>
<display
value="LUNG NSCLC NON-Metastatic - cISplatin and gemcitabine chemoradiation"/>
</concept>
<concept>
<code value="59281000210103"/>
<display value="LUNG NSCLC Metastatic - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="59271000210100"/>
<display
value="LUNG NSCLC NON-Metastatic - cISplatin and vinBLASTine chemoradiation"/>
</concept>
<concept>
<code value="59261000210106"/>
<display value="GU PROS Metastatic - zoledronic acid Q6W"/>
</concept>
<concept>
<code value="59251000210108"/>
<display value="HN SQCC Metastatic - nivolumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="59241000210105"/>
<display
value="HN SQCC NON-Metastatic - cISplatin [Q1W] post-operative chemoradiation"/>
</concept>
<concept>
<code value="59231000210102"/>
<display
value="HN SQCC NON-Metastatic - cARBOplatin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="59221000210104"/>
<display
value="HN SQCC Metastatic - nivolumab [weight-based dosing]"/>
</concept>
<concept>
<code value="59211000210109"/>
<display
value="HN SQCC Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="59201000210107"/>
<display
value="HN SQCC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="59191000210105"/>
<display
value="BR Metastatic - capecitabine 1000 and trastuzumab Q3W"/>
</concept>
<concept>
<code value="59181000210108"/>
<display value="BR Metastatic - DOCEtaxel Q3W"/>
</concept>
<concept>
<code value="59171000210106"/>
<display
value="BR Metastatic - DOCEtaxel, pERTUZumab and trastuzumab"/>
</concept>
<concept>
<code value="59161000210100"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W"/>
</concept>
<concept>
<code value="59151000210103"/>
<display value="BR Metastatic - DOCEtaxel and trastuzumab Q3W"/>
</concept>
<concept>
<code value="59141000210101"/>
<display
value="BR NON-Metastatic - FEC-D75 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]"/>
</concept>
<concept>
<code value="59131000210109"/>
<display
value="BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="59121000210107"/>
<display
value="BR NON-Metastatic - AC-TH [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by [DOCEtaxel and trastuzumab] Q3W"/>
</concept>
<concept>
<code value="59111000210102"/>
<display value="UGI GAST AND OES Metastatic - DOCEtaxel"/>
</concept>
<concept>
<code value="59101000210104"/>
<display
value="UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="59091000210106"/>
<display
value="UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="59081000210109"/>
<display
value="UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="59071000210107"/>
<display
value="UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="59051000210104"/>
<display
value="UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="59041000210102"/>
<display
value="UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="59031000210105"/>
<display
value="UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="59021000210108"/>
<display
value="SKIN Melanoma NON-Metastatic - daBRAFEnib and tRAMEtinib"/>
</concept>
<concept>
<code value="59011000210103"/>
<display value="LUNG NSCLC Metastatic - gefitinib"/>
</concept>
<concept>
<code value="59001000210100"/>
<display
value="LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 60/120 chemoradiation"/>
</concept>
<concept>
<code value="58991000210100"/>
<display
value="LUNG SCLC Extensive - cARBOplatin and oral etoposide"/>
</concept>
<concept>
<code value="58981000210102"/>
<display
value="LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q4W"/>
</concept>
<concept>
<code value="58971000210104"/>
<display
value="LUNG SCLC Metastatic - [Extensive] cISplatin and irinotecan"/>
</concept>
<concept>
<code value="58961000210105"/>
<display value="LUNG SCLC Extensive - cARBOplatin and etoposide"/>
</concept>
<concept>
<code value="58951000210107"/>
<display value="LUNG NSCLC Metastatic - erlotinib"/>
</concept>
<concept>
<code value="58941000210109"/>
<display value="LUNG NSCLC Metastatic - cISplatin and pemetrexed"/>
</concept>
<concept>
<code value="58931000210101"/>
<display
value="SKIN Melanoma Metastatic - daBRAFEnib and tRAMEtinib"/>
</concept>
<concept>
<code value="58921000210103"/>
<display
value="LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q3W"/>
</concept>
<concept>
<code value="58911000210108"/>
<display value="LUNG NSCLC Metastatic - cISplatin and vinORELBine"/>
</concept>
<concept>
<code value="58901000210106"/>
<display
value="LUNG NSCLC NON-Metastatic - cARBOplatin and PACLItaxel chemoradiation"/>
</concept>
<concept>
<code value="58891000210105"/>
<display value="LUNG NSCLC Metastatic - cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="58881000210108"/>
<display
value="BR Metastatic - CYCLOPHOSPHamide and metHOTREXATe [low dose oral]"/>
</concept>
<concept>
<code value="58871000210106"/>
<display
value="BR NON-Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]"/>
</concept>
<concept>
<code value="58861000210100"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and and CYCLOPHOSPHamide] dose dense followed by PACLItaxel dose dense"/>
</concept>
<concept>
<code value="58851000210103"/>
<display value="BR NON-Metastatic - capecitabine"/>
</concept>
<concept>
<code value="58841000210101"/>
<display value="BR Metastatic - zoledronic acid Q12W"/>
</concept>
<concept>
<code value="58831000210109"/>
<display
value="BR NON-Metastatic - TCy and trastuzumab [DOCEtaxel, CYCLOPHOSPHamide and trastuzumab]"/>
</concept>
<concept>
<code value="58821000210107"/>
<display value="BR NON-Metastatic - trastuzumab Q3W"/>
</concept>
<concept>
<code value="58811000210102"/>
<display value="BR NON-Metastatic - trastuzumab subcutaneous"/>
</concept>
<concept>
<code value="58801000210104"/>
<display value="BR NON-Metastatic - exemestane and goserelin"/>
</concept>
<concept>
<code value="58791000210103"/>
<display
value="BR NON-Metastatic - PACLItaxel Q1W and trastuzumab Q3W"/>
</concept>
<concept>
<code value="58781000210100"/>
<display
value="BR NON-Metastatic - FEC-D100 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]"/>
</concept>
<concept>
<code value="58771000210102"/>
<display
value="BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] Q3W"/>
</concept>
<concept>
<code value="58761000210108"/>
<display value="BR NON-Metastatic - zoledronic acid"/>
</concept>
<concept>
<code value="58751000210105"/>
<display value="BR NON-Metastatic - neratinib"/>
</concept>
<concept>
<code value="58741000210107"/>
<display
value="BR NON-Metastatic - TCH [DOCEtaxel, cARBOplatin and trastuzumab]"/>
</concept>
<concept>
<code value="58731000210104"/>
<display value="BR NON-Metastatic - PACLItaxel Q1W"/>
</concept>
<concept>
<code value="58721000210101"/>
<display value="BR NON-Metastatic - Kadcyla [trastuzumab emtansine]"/>
</concept>
<concept>
<code value="58711000210106"/>
<display
value="BR NON-Metastatic - TCy [DOCEtaxel and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="58701000210109"/>
<display value="BR Metastatic - zoledronic acid Q4W"/>
</concept>
<concept>
<code value="58691000210109"/>
<display
value="BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W"/>
</concept>
<concept>
<code value="58681000210107"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W and trastuzumab Q3W"/>
</concept>
<concept>
<code value="58671000210105"/>
<display value="BR Metastatic - capecitabine 1250"/>
</concept>
<concept>
<code value="58661000210104"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by DOCEtaxel Q3W"/>
</concept>
<concept>
<code value="58651000210102"/>
<display value="BR Metastatic - trastuzumab Q3W"/>
</concept>
<concept>
<code value="58641000210100"/>
<display value="BR Metastatic - DOXOrubicin Q3W"/>
</concept>
<concept>
<code value="58631000210108"/>
<display value="BR Metastatic - eribulin"/>
</concept>
<concept>
<code value="58621000210106"/>
<display
value="BR Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W"/>
</concept>
<concept>
<code value="58611000210101"/>
<display value="BR Metastatic - DOXOrubicin Q1W"/>
</concept>
<concept>
<code value="58601000210103"/>
<display value="BR Metastatic - cARBOplatin [5 AUC] and gemcitabine"/>
</concept>
<concept>
<code value="58591000210108"/>
<display value="BR Metastatic - gemcitabine"/>
</concept>
<concept>
<code value="58581000210106"/>
<display value="BR Metastatic - PACLItaxel Q1W and trastuzumab Q3W"/>
</concept>
<concept>
<code value="58571000210109"/>
<display value="BR Metastatic - pamidronate"/>
</concept>
<concept>
<code value="58561000210103"/>
<display value="BR Metastatic - goserelin Q12W"/>
</concept>
<concept>
<code value="58551000210101"/>
<display value="BR Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="58541000210104"/>
<display value="BR Metastatic - fulvestrant"/>
</concept>
<concept>
<code value="58531000210107"/>
<display value="BR Metastatic - denosumab"/>
</concept>
<concept>
<code value="58521000210105"/>
<display
value="BR Metastatic - MMM [mitomycin, mitoxantrone and metHOTREXATe]"/>
</concept>
<concept>
<code value="58511000210100"/>
<display value="BR Metastatic - Kadcyla [trastuzumab emtansine]"/>
</concept>
<concept>
<code value="58501000210102"/>
<display value="BR Metastatic - PACLItaxel Q1W"/>
</concept>
<concept>
<code value="58491000210107"/>
<display value="BR Metastatic - everolimus and exemestane"/>
</concept>
<concept>
<code value="58481000210105"/>
<display
value="BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] and aTEZOLIzumab"/>
</concept>
<concept>
<code value="58471000210108"/>
<display
value="BR Metastatic - trastuzumab Q3W and vinORELBine [oral]"/>
</concept>
<concept>
<code value="58461000210102"/>
<display
value="BR Metastatic - trastuzumab Q3W and vinORELBine [IV]"/>
</concept>
<concept>
<code value="57851000210102"/>
<display
value="BR NON-Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W"/>
</concept>
<concept>
<code value="57841000210100"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W"/>
</concept>
<concept>
<code value="57831000210108"/>
<display value="BR Metastatic - trastuzumab subcutaneous"/>
</concept>
<concept>
<code value="57821000210106"/>
<display value="BR Metastatic - vinORELBine [IV]"/>
</concept>
<concept>
<code value="57811000210101"/>
<display value="BR Metastatic - palbociclib"/>
</concept>
<concept>
<code value="57801000210103"/>
<display value="BR Metastatic - goserelin Q4W"/>
</concept>
<concept>
<code value="57791000210102"/>
<display value="BR Metastatic - cARBOplatin"/>
</concept>
<concept>
<code value="57781000210104"/>
<display
value="BR Metastatic - EC [epirubicin and CYCLOPHOSPHamide]"/>
</concept>
<concept>
<code value="57771000210101"/>
<display value="BR Metastatic - vinORELBine [IV] Q1W"/>
</concept>
<concept>
<code value="57761000210107"/>
<display
value="BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense"/>
</concept>
<concept>
<code value="57751000210109"/>
<display
value="UGI PANC NON-Metastatic - capecitabine and gemcitabine [advanced]"/>
</concept>
<concept>
<code value="57741000210106"/>
<display
value="UGI PANC NON-Metastatic - capecitabine and gemcitabine [adjuvant]"/>
</concept>
<concept>
<code value="57731000210103"/>
<display
value="UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="57721000210100"/>
<display
value="UGI PANC Metastatic - PDXG [DOCEtaxel, gemcitabine, ciSplatin and capecitabine]"/>
</concept>
<concept>
<code value="57711000210105"/>
<display value="UGI PANC NON-Metastatic - gemcitabine [adjuvant]"/>
</concept>
<concept>
<code value="57701000210108"/>
<display value="UGI PANC Metastatic - olaparib"/>
</concept>
<concept>
<code value="57691000210108"/>
<display value="UGI PANC NON-Metastatic - gemcitabine [advanced]"/>
</concept>
<concept>
<code value="57681000210106"/>
<display
value="UGI PANC NON-Metastatic - capecitabine chemoradiation [continuous dosing]"/>
</concept>
<concept>
<code value="57671000210109"/>
<display
value="UGI PANC NON-Metastatic - capecitabine chemoradiation [5 day dosing]"/>
</concept>
<concept>
<code value="57661000210103"/>
<display
value="SKIN SQCC Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="57651000210101"/>
<display
value="SKIN SQCC Metastatic - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="57641000210104"/>
<display
value="SKIN SQCC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="57631000210107"/>
<display
value="SKIN Melanoma NON-Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="57621000210105"/>
<display
value="SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="57611000210100"/>
<display
value="SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="57601000210102"/>
<display
value="SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="57591000210107"/>
<display
value="SKIN Melanoma NON-Metastatic - nivolumab Q2W [weight based dosing]"/>
</concept>
<concept>
<code value="57581000210105"/>
<display
value="SKIN Melanoma NON-Metastatic - nivolumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="57571000210108"/>
<display
value="SKIN Melanoma Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="57561000210102"/>
<display
value="SKIN Melanoma Metastatic - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="57551000210100"/>
<display
value="SKIN Melanoma Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="57541000210103"/>
<display
value="SKIN Melanoma Metastatic - nivolumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="57531000210106"/>
<display
value="SKIN Melanoma Metastatic - nivolumab Q2W [weight based dosing]"/>
</concept>
<concept>
<code value="57521000210109"/>
<display
value="SKIN Melanoma Metastatic - nivolumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="57511000210104"/>
<display
value="SKIN Melanoma Metastatic - ipilimumab and pembrolizumab"/>
</concept>
<concept>
<code value="57501000210101"/>
<display
value="SKIN Melanoma Metastatic - ipilimumab 3mg/kg and nivolumab 1mg/kg"/>
</concept>
<concept>
<code value="57491000210106"/>
<display
value="SKIN Melanoma Metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg"/>
</concept>
<concept>
<code value="57481000210109"/>
<display value="SKIN Melanoma Metastatic - imatinib"/>
</concept>
<concept>
<code value="57471000210107"/>
<display value="SKIN Melanoma Metastatic - dacarbazine"/>
</concept>
<concept>
<code value="57461000210101"/>
<display
value="SKIN Melanoma Metastatic - cOBIMEtinib and vemurafenib"/>
</concept>
<concept>
<code value="57451000210104"/>
<display
value="SKIN Melanoma Metastatic - cARBOplatin, PACLItaxel, and beVACizumab"/>
</concept>
<concept>
<code value="57441000210102"/>
<display value="SKIN BCC Metastatic - vismodegib"/>
</concept>
<concept>
<code value="57431000210105"/>
<display
value="SKIN MCC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="57421000210108"/>
<display
value="SKIN MCC Metastatic - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="57411000210103"/>
<display
value="SKIN MCC Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="57401000210100"/>
<display
value="SKIN Melanoma Metastatic - biNIMEtinib and encorafenib"/>
</concept>
<concept>
<code value="57391000210103"/>
<display
value="LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide"/>
</concept>
<concept>
<code value="57381000210100"/>
<display
value="LUNG SCLC NON-Metastatic - [Limited] cARBOplatin and etoposide"/>
</concept>
<concept>
<code value="57371000210102"/>
<display
value="LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 750, DOXOrubicin and vinCRISTine]"/>
</concept>
<concept>
<code value="57361000210108"/>
<display value="UGI HEP Metastatic - leNVAtinib"/>
</concept>
<concept>
<code value="57351000210105"/>
<display value="UGI HEP Metastatic - aTEZOLIzumab and beVACizumab"/>
</concept>
<concept>
<code value="57341000210107"/>
<display value="UGI HEP Metastatic - aTEZOLIzumab"/>
</concept>
<concept>
<code value="57331000210104"/>
<display value="UGI GIST NON-Metastatic - imatinib"/>
</concept>
<concept>
<code value="57321000210101"/>
<display value="UGI GIST Metastatic - sUNITinib [4/2 dosing]"/>
</concept>
<concept>
<code value="57311000210106"/>
<display
value="UGI GAST Metastatic - cISplatin, capecitabine and pembrolizumab [flat dose]"/>
</concept>
<concept>
<code value="57301000210109"/>
<display
value="UGI GAST AND OES Metastatic - cISplatin, fluorouracil and trastuzumab"/>
</concept>
<concept>
<code value="57291000210105"/>
<display
value="UGI GAST AND OES Metastatic - cISplatin, capecitabine and trastuzumab"/>
</concept>
<concept>
<code value="57281000210108"/>
<display
value="UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="57271000210106"/>
<display
value="UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="57261000210100"/>
<display
value="UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="54251000210109"/>
<display
value="UGI GAST AND OES Metastatic - cISplatin and fluorouracil"/>
</concept>
<concept>
<code value="54241000210106"/>
<display
value="UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="54231000210103"/>
<display
value="UGI BIL AND GBC Metastatic - cARBOplatin and gemcitabine"/>
</concept>
<concept>
<code value="54221000210100"/>
<display value="UGI BIL AND GBC Metastatic - gemcitabine"/>
</concept>
<concept>
<code value="54211000210105"/>
<display
value="UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="54201000210108"/>
<display
value="UGI GAST AND OES Metastatic - trifluridine/tipiracil"/>
</concept>
<concept>
<code value="54191000210106"/>
<display value="UGI BIL AND GBC NON-Metastatic - capecitabine"/>
</concept>
<concept>
<code value="54181000210109"/>
<display
value="UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="54171000210107"/>
<display value="UGI PANC Metastatic - gemcitabine"/>
</concept>
<concept>
<code value="54161000210101"/>
<display value="UGI GIST Metastatic - sUNITinib [2/1 dosing]"/>
</concept>
<concept>
<code value="54151000210104"/>
<display
value="UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="54131000210105"/>
<display value="UGI HEP Metastatic - soRAFENib"/>
</concept>
<concept>
<code value="54121000210108"/>
<display
value="UGI GAST AND OES Metastatic - cISplatin and capecitabine"/>
</concept>
<concept>
<code value="54111000210103"/>
<display
value="UGI GAST AND OES Metastatic - pembrolizumab Q3W [weight based dosing]"/>
</concept>
<concept>
<code value="54101000210100"/>
<display value="UGI GAST AND OES Metastatic - raMUCIRumab"/>
</concept>
<concept>
<code value="54091000210107"/>
<display
value="UGI GAST AND OES Metastatic - PACLItaxel and raMUCIRumab"/>
</concept>
<concept>
<code value="54081000210105"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="54071000210108"/>
<display
value="UGI GAST NON-Metastatic - fluorouracil chemoradiation [modified MacDonald]"/>
</concept>
<concept>
<code value="54061000210102"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="53971000210106"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and trastuzumab"/>
</concept>
<concept>
<code value="53071000210105"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="53061000210104"/>
<display
value="UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin]"/>
</concept>
<concept>
<code value="53051000210102"/>
<display
value="UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="53041000210100"/>
<display value="UGI GIST Metastatic - imatinib"/>
</concept>
<concept>
<code value="53031000210108"/>
<display
value="UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="53021000210106"/>
<display
value="UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation [MSKCC]"/>
</concept>
<concept>
<code value="53011000210101"/>
<display
value="UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="53001000210103"/>
<display
value="UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation [Herskovic]"/>
</concept>
<concept>
<code value="52991000210102"/>
<display value="UGI GIST Metastatic - regorafenib"/>
</concept>
<concept>
<code value="52981000210104"/>
<display
value="UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52971000210101"/>
<display
value="UGI GAST AND OES Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="52961000210107"/>
<display
value="UGI GAST NON-Metastatic - CAPOX [capecitabine and oxaliplatin]"/>
</concept>
<concept>
<code value="52951000210109"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and trastuzumab"/>
</concept>
<concept>
<code value="52941000210106"/>
<display
value="UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and trastuzumab"/>
</concept>
<concept>
<code value="52931000210103"/>
<display
value="UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52921000210100"/>
<display value="UGI GAST AND OES Metastatic - irinotecan Q2W"/>
</concept>
<concept>
<code value="52911000210105"/>
<display
value="UGI GAST AND OES Metastatic - PACLItaxel weekly [3/1 dosing]"/>
</concept>
<concept>
<code value="52901000210108"/>
<display
value="UGI GAST AND OES Metastatic - PACLItaxel weekly [continuous dosing]"/>
</concept>
<concept>
<code value="52891000210107"/>
<display
value="UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52881000210105"/>
<display
value="UGI OES NON-Metastatic - cARBOplatin and PACLItaxel Q1W chemoradiation"/>
</concept>
<concept>
<code value="52871000210108"/>
<display
value="LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 1000, DOXOrubicin and vinCRISTine]"/>
</concept>
<concept>
<code value="52861000210102"/>
<display value="LUNG NSCLC NON-Metastatic - crizotinib"/>
</concept>
<concept>
<code value="52851000210100"/>
<display
value="LUNG NSCLC NON-Metastatic - cISplatin and etoposide chemoradiation"/>
</concept>
<concept>
<code value="52841000210103"/>
<display
value="LUNG NSCLC NON-Metastatic - [Superior sulcus Pancoast] cISplatin and etoposide chemoradiation"/>
</concept>
<concept>
<code value="52831000210106"/>
<display value="LUNG NSCLC Metastatic - cARBOplatin and DOCEtaxel"/>
</concept>
<concept>
<code value="52821000210109"/>
<display value="LUNG NSCLC Metastatic - cARBOplatin and pemetrexed"/>
</concept>
<concept>
<code value="52811000210104"/>
<display value="LUNG NSCLC Metastatic - DOCEtaxel Q3W"/>
</concept>
<concept>
<code value="52801000210101"/>
<display value="LUNG NSCLC Metastatic - DOCEtaxel Q1W"/>
</concept>
<concept>
<code value="52791000210100"/>
<display
value="CRC REC Metastatic - capecitabine chemoradiation [continuous dosing]"/>
</concept>
<concept>
<code value="52781000210102"/>
<display value="LUNG NSCLC NON-Metastatic - durvalumab"/>
</concept>
<concept>
<code value="52771000210104"/>
<display value="LUNG NSCLC NON-Metastatic - aTEZOLIzumab"/>
</concept>
<concept>
<code value="52761000210105"/>
<display value="LUNG NSCLC Metastatic - nivolumab Q4W [flat dosing]"/>
</concept>
<concept>
<code value="52751000210107"/>
<display
value="LUNG NSCLC Metastatic - nivolumab Q2W [weight based dosing]"/>
</concept>
<concept>
<code value="52741000210109"/>
<display value="LUNG NSCLC Metastatic - daBRAFEnib and tRAMEtinib"/>
</concept>
<concept>
<code value="52731000210101"/>
<display value="LUNG NSCLC Metastatic - aTEZOLIzumab"/>
</concept>
<concept>
<code value="52721000210103"/>
<display value="LUNG NSCLC Metastatic - aFATinib"/>
</concept>
<concept>
<code value="52711000210108"/>
<display value="LUNG MESO Metastatic - cISplatin and pemetrexed"/>
</concept>
<concept>
<code value="52701000210106"/>
<display value="LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing]"/>
</concept>
<concept>
<code value="52691000210106"/>
<display value="LUNG MESO Metastatic - cARBOplatin and pemetrexed"/>
</concept>
<concept>
<code value="52681000210109"/>
<display value="LUNG NSCLC Metastatic - PACLItaxel Q1W"/>
</concept>
<concept>
<code value="52671000210107"/>
<display
value="LUNG NSCLC Metastatic - cARBOplatin, pemetrexed and pembrolizumab"/>
</concept>
<concept>
<code value="52661000210101"/>
<display value="LUNG NSCLC Metastatic - crizotinib"/>
</concept>
<concept>
<code value="52651000210104"/>
<display
value="LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel and pembrolizumab"/>
</concept>
<concept>
<code value="52641000210102"/>
<display
value="LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel, aTEZOLIzumab and beVACizumab"/>
</concept>
<concept>
<code value="52631000210105"/>
<display
value="CRC REC Metastatic - capecitabine chemoradiation [5 day dosing]"/>
</concept>
<concept>
<code value="52621000210108"/>
<display
value="CRC Adjuvant - mRoswell Park [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52611000210103"/>
<display
value="CRC Metastatic - mDe Gramont [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52601000210100"/>
<display value="CRC REC Metastatic - fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="52591000210105"/>
<display
value="CRC Metastatic - mDe Gramont [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52581000210108"/>
<display value="BR Metastatic - capecitabine 1000"/>
</concept>
<concept>
<code value="52571000210106"/>
<display value="LUNG MESO Metastatic - vinORELBine"/>
</concept>
<concept>
<code value="52561000210100"/>
<display
value="GU PROS Castration resistant Metastatic - cARBOplatin and DOCEtaxel"/>
</concept>
<concept>
<code value="52551000210103"/>
<display
value="LUNG NSCLC Metastatic - cARBOplatin and Q1W PACLItaxel"/>
</concept>
<concept>
<code value="52541000210101"/>
<display value="GU PROS Metastatic - zoledronic acid Q12W"/>
</concept>
<concept>
<code value="52531000210109"/>
<display
value="GU PROS Castration resistant Metastatic - enzalutamide"/>
</concept>
<concept>
<code value="52521000210107"/>
<display value="GU PROS Metastatic - zoledronic acid Q4W"/>
</concept>
<concept>
<code value="52511000210102"/>
<display
value="GU PROS Castration resistant Metastatic - cabazitaxel Q3W and prEDNISone"/>
</concept>
<concept>
<code value="52501000210104"/>
<display value="CRC Metastatic - raltitrexed and oxaliplatin"/>
</concept>
<concept>
<code value="52491000210109"/>
<display
value="CRC Adjuvant - mRoswell Park [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52481000210107"/>
<display
value="CRC Metastatic - mRoswell Park [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52471000210105"/>
<display value="CRC Metastatic - raltitrexed"/>
</concept>
<concept>
<code value="52461000210104"/>
<display value="GU PROS Metastatic - goserelin"/>
</concept>
<concept>
<code value="52451000210102"/>
<display
value="GU PROS Castration resistant Metastatic - abiraterone and dexamethasone"/>
</concept>
<concept>
<code value="52441000210100"/>
<display
value="GU PROS Castration resistant NON-Metastatic - apalutamide"/>
</concept>
<concept>
<code value="52431000210108"/>
<display
value="GU PROS Castration sensitive Metastatic - apalutamide"/>
</concept>
<concept>
<code value="52421000210106"/>
<display value="GU PROS Metastatic - bicalutamide"/>
</concept>
<concept>
<code value="52411000210101"/>
<display value="GU PROS Metastatic - flutamide"/>
</concept>
<concept>
<code value="52401000210103"/>
<display value="LUNG NSCLC NON-Metastatic - alectinib"/>
</concept>
<concept>
<code value="52391000210101"/>
<display
value="GU PROS Castration resistant Metastatic - DOCEtaxel Q2W and prEDNISone"/>
</concept>
<concept>
<code value="52381000210103"/>
<display
value="GU PROS Castration resistant Metastatic - DOCEtaxel Q3W and prEDNISone"/>
</concept>
<concept>
<code value="52371000210100"/>
<display
value="GU PROS Castration sensitive Metastatic - abiraterone and prEDNISone"/>
</concept>
<concept>
<code value="52361000210106"/>
<display
value="GU PROS Castration sensitive Metastatic - DOCEtaxel Q3W"/>
</concept>
<concept>
<code value="52351000210108"/>
<display value="GU PROS Metastatic - cyproterone"/>
</concept>
<concept>
<code value="52341000210105"/>
<display value="GU PROS Metastatic - pembrolizumab [flat dose]"/>
</concept>
<concept>
<code value="52331000210102"/>
<display value="LUNG NSCLC Advanced/Metastatic - alectinib"/>
</concept>
<concept>
<code value="52321000210104"/>
<display
value="GU PROS Castration resistant Metastatic - abiraterone and prEDNISone"/>
</concept>
<concept>
<code value="52311000210109"/>
<display
value="GU PROS Castration resistant Metastatic - abiraterone and prEDNISone [fed state]"/>
</concept>
<concept>
<code value="52301000210107"/>
<display
value="CRC Metastatic - mFOLFOXIRI with beVACizumab [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52291000210108"/>
<display
value="CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52281000210106"/>
<display
value="CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52271000210109"/>
<display
value="CRC Metastatic - mFOLFOXIRI [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52261000210103"/>
<display value="CRC Metastatic - mFOLFOXIRI [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52251000210101"/>
<display
value="CRC Metastatic - mFOLFOXIRI with beVACizumab [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52241000210104"/>
<display
value="CRC Metastatic - mRoswell Park [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52231000210107"/>
<display
value="CRC REC Locally advanced - fluorouracil chemoradiation"/>
</concept>
<concept>
<code value="52221000210105"/>
<display
value="CRC REC Locally advanced - capecitabine chemoradiation [continuous dosing]"/>
</concept>
<concept>
<code value="52211000210100"/>
<display
value="CRC REC Locally advanced - capecitabine chemoradiation [5 day dosing]"/>
</concept>
<concept>
<code value="52201000210102"/>
<display value="CRC Adjuvant - mFOLFOX6 [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52191000210104"/>
<display value="CRC Adjuvant - mFOLFOX6 [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52181000210101"/>
<display value="CRC Adjuvant - CAPOX"/>
</concept>
<concept>
<code value="52171000210103"/>
<display value="CRC Adjuvant - capecitabine"/>
</concept>
<concept>
<code value="52161000210109"/>
<display value="CRC Metastatic - regorafenib"/>
</concept>
<concept>
<code value="52151000210106"/>
<display
value="CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52141000210108"/>
<display
value="CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52131000210100"/>
<display
value="CRC Metastatic - mFOLFOX6 and beVACizumab [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52121000210102"/>
<display
value="CRC Metastatic - mFOLFOX6 and beVACizumab [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52111000210107"/>
<display value="CRC Metastatic - mFOLFOX6 [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52101000210105"/>
<display value="CRC Metastatic - mFOLFOX6 [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="52091000210103"/>
<display
value="CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="52081000210100"/>
<display value="CRC Metastatic - CAPOX"/>
</concept>
<concept>
<code value="52071000210102"/>
<display value="CRC Metastatic - capecitabine 1000"/>
</concept>
<concept>
<code value="52061000210108"/>
<display value="CRC Metastatic - capecitabine 1250"/>
</concept>
<concept>
<code value="52051000210105"/>
<display value="CRC Metastatic - capecitabine and beVACizumab"/>
</concept>
<concept>
<code value="52041000210107"/>
<display value="CRC Metastatic - capecitabine and mitomycin"/>
</concept>
<concept>
<code value="52031000210104"/>
<display value="CRC Metastatic - CAPOX and beVACizumab"/>
</concept>
<concept>
<code value="52021000210101"/>
<display value="CRC Metastatic - CETUximab [Q1W]"/>
</concept>
<concept>
<code value="52011000210106"/>
<display
value="CRC Metastatic - CETUximab [Q1W] and irinotecan [Q2W]"/>
</concept>
<concept>
<code value="52001000210109"/>
<display value="CRC Metastatic - CETUximab and irinotecan [Q2W]"/>
</concept>
<concept>
<code value="51991000210106"/>
<display value="CRC Metastatic - irinotecan Q3W"/>
</concept>
<concept>
<code value="51981000210109"/>
<display value="CRC Metastatic - IrOX"/>
</concept>
<concept>
<code value="51971000210107"/>
<display value="CRC Metastatic - mCAPIRI"/>
</concept>
<concept>
<code value="51961000210101"/>
<display value="CRC Metastatic - mFOLFIRI [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="51951000210104"/>
<display value="CRC Metastatic - mFOLFIRI [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="51941000210102"/>
<display
value="CRC Metastatic - mFOLFIRI and beVACizumab [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="51931000210105"/>
<display
value="CRC Metastatic - mFOLFIRI and beVACizumab [low dose foliNIc acid]"/>
</concept>
<concept>
<code value="51921000210108"/>
<display
value="CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [high dose foliNIc acid]"/>
</concept>
<concept>
<code value="51911000210103"/>
<display value="CRC Metastatic - FLOX"/>
</concept>
<concept>
<code value="51901000210100"/>
<display value="CRC Adjuvant - mQUASAR"/>
</concept>
<concept>
<code value="51891000210101"/>
<display value="CRC Adjuvant - MAYO"/>
</concept>
<concept>
<code value="51881000210103"/>
<display value="CRC Metastatic - mQUASAR"/>
</concept>
</include>
</compose>
</ValueSet>